The efficacy and safety as a single agent were demonstrated in two pivotal phase 2 studies; brentuximab vedotin led to an objective response rate of 75% in patients with histologically documented CD30+ relapsed or refractory Hodgkin lymphoma, leading to complete remission in 33% of the patients and tumor reductions detected in 94% [41]. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.